Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
IPO Year: 2015
Exchange: NYSE
Website: invitae.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/5/2023 | Underweight | JP Morgan | |
| 5/15/2023 | Mkt Perform → Underperform | Raymond James | |
| 1/31/2023 | $2.00 | Neutral → Sell | Goldman |
| 8/25/2022 | $1.00 | Underperform | Credit Suisse |
| 8/10/2022 | Neutral → Underweight | JP Morgan | |
| 7/26/2022 | $8.00 → $2.50 | Outperform → Market Perform | Cowen |
| 7/21/2022 | Outperform → Mkt Perform | Raymond James | |
| 7/20/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 7/19/2022 | Buy → Hold | The Benchmark Company | |
| 7/19/2022 | Outperform → Mkt Perform | SVB Leerink |
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c
– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.
– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a novel machine learning approach designed to aid clinical interpretation of genetic testing results and increase the rate of definitive answers for patients. The first of its kind, developed by a multidisciplinary team of computational biologists, machine learning engineers, clinical experts and geneticists, Clinical Variant Modeling methodically leverages clinical information received at the time of tes
SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> Estimated unaudited financial results for fourth quarter 2023 Fourth quarter 2023 revenue was $127.8 mil
– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC:NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mis
– Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO, Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders.
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic info
SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ:NTRA). www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> The value of the transaction is up
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
JP Morgan resumed coverage of Invitae with a rating of Underweight
Raymond James downgraded Invitae from Mkt Perform to Underperform
Goldman downgraded Invitae from Neutral to Sell and set a new price target of $2.00
Credit Suisse initiated coverage of Invitae with a rating of Underperform and set a new price target of $1.00
JP Morgan downgraded Invitae from Neutral to Underweight
Cowen downgraded Invitae from Outperform to Market Perform and set a new price target of $2.50 from $8.00 previously
Raymond James downgraded Invitae from Outperform to Mkt Perform
Ladenburg Thalmann downgraded Invitae from Buy to Neutral
The Benchmark Company downgraded Invitae from Buy to Hold
SVB Leerink downgraded Invitae from Outperform to Mkt Perform
Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc
SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu
– Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth – SAN FRANCISCO, Aug. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of
– Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development – – Invitae reports inducement grant under NYSE Rule 303A.08 – SAN FRANCISCO, March 16, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn, M.D., as its chief medical officer for oncology, effective March 13, 2023. Dr. Korn brings decades of experience in the field of gastrointestinal cancers, implementing precision oncology principles in clinical cancer care, and designing a novel database on targeted cancer therapeutics.
– Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO, Jan. 30, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, has announced that aerospace, transportation and industrial supplies veteran William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practi
— COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — — Co-Founder and former CEO Randy Scott returns as chairman — — Current chairman Eric Aguiar to serve as lead independent director — SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders. Specifically, Kenneth D. Knight, who has served as Invitae's chief operating officer since 2020, is succeeding Sean George
CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D'Angelo and Omar Elbakshish to the company's management team, expanding its global leadership to help scale the growing business. "We are thrilled to welcome Andre, Dalila, Laura and Omar to the expanding leadership team here at Dante," said Andrea Riposati, CEO of Dante Labs. "As we work to deliver a more human approach to healthcare, it is our shared vision of the future and growing importance genomics is playing in healthcare that will help to meet the unmet needs of our customers from whole g
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion. "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di
SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global technology and medical technology companies. "We're delighted Roxi will be joining our team. Her track record of driving growth, financial management and execution of unique business models in the U.S. and international markets across technology and life science settings is well suited to our goals," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "In addition to her expertise,
4 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
3 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
3 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
3 - Invitae Corp (0001501134) (Issuer)
3 - Invitae Corp (0001501134) (Issuer)
25-NSE - Invitae Corp (0001501134) (Subject)
8-K - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
8-K/A - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
8-K/A - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
8-K - Invitae Corp (0001501134) (Filer)
Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%. The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign currency translation of 0.5%. The 2.3% increase in organic revenue was driven by a 4.2% increase in the company’s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing). The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago. Diagnostics Laboratories revenue for the quarter was $2.48 billion, an increase of 4.1%. Total volume
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024
SoftBank Group Corp (OTC:SFTBY) (OTC:SFTBF) backed Cohesity has agreed to the acquisition of the data protection business of Veritas Technologies LLC. The deal is valued at $3 billion, creating a combined entity worth $7 billion. What Happened: Cohesity, a U.S.-based data security software company, is set to acquire the data protection business of Veritas, a subsidiary of Carlyle Group Inc (NASDAQ:CG). The deal, comprising cash and stock, is expected to be finalized by the end of the year, as per source-based report by Reuters. The acquisition is anticipated to bolster Cohesity’s growth margins and facilitate its expansion into international markets. The combined annual revenue of the
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.25% to 38,618.79 while the NASDAQ rose 0.34% to 15,661.70. The S&P 500 also rose, gaining, 0.34% to 4,971.18. Check This Out: Top 5 Energy Stocks That May Explode In February Leading and Lagging Sectors Consumer discretionary shares rose by 0.7% on Wednesday. In trading on Wednesday, utilities shares fell by 0.2%. Top Headline Uber Technologies, Inc (NYSE:UBER) reported better-than-expected fourth-quarter sales. Uber reported fourth-quarter FY23 revenue growth of 15% year-on-year to $9.94 billion, beating the cons
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options, and bankruptcy is a prominent consideration. The company, known for its aggressive acquisition approach in recent years, has initiated the shedding of assets and cost-cutting measures to add
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock increased by 75.2% to $30.64 during Monday's regular session. The company's market cap stands at $1.3 billion. Yield10 Bioscience (NASDAQ:YTEN) stock rose 61.76% to $0.37. The market value of their outstanding shares is at $4.4 million. MorphoSys (NASDAQ:MOR) stock moved upwards by 50.76% to $16.69. The market value of their outstanding shares is at $2.5 billion. Karyopharm Therapeutics (NASDAQ:KPTI) shares moved upwards by 31.73% to $1.37. The company's market cap stands at $156.9 million. Adverum Biotechnologies (NASDAQ:ADVM) stock moved upwards by 28.86% to $1.83. The company's market cap stands at $184.8 million. Mira Pharmaceut
https://www.wsj.com/articles/softbank-backed-medical-genetics-company-invitae-prepares-for-bankruptcy-d468f120?st=02yzwzf1bnabmx0&mod=googlenewsfeed Invitae, a medical genetics company that received backing from SoftBank Group at the height of the pandemic has hired restructuring advisers and is preparing to file for bankruptcy within weeks, according to people familiar with the matter. The company is working with FTI Consulting and law firm Kirkland & Ellis to explore strategic options, including bankruptcy, to address $1.5 billion in debt on its balance sheet, the people said.
Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o
– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year – – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res
SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">
– Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% – – Continued improvement in gross margin and ongoing cash burn trends – – Company reiterates key 2023 financial guidance metrics – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2023. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invit
SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">
– In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holders to exchange 90% of their existing 2024 notes for new notes due in 2028 and equitize 10% of their holdings; Certain investors will also provide an additional $30 million of capital – – The Company will discuss this announcement during its fourth quarter and full year 2022 earnings call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has signed exchange and financing agreements with a fund managed by Deerfield Man
SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae
— Approximately 12% growth year-over-year in revenues —— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —— Cash burn continued its declining trend over the past five quarters —— Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m. PST — SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced preliminary unaudited fourth quarter and full-year 2022 revenue, cash burn and commercial metrics. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring
Addition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider Integrated DNA Technologies, Inc. (IDT) today announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE:NVTA) under the trademarked name Archer®. The integration of IDT's portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and wel
SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">